Northwestern University Feinberg School of Medicine

Alexander Stegh Lab

Publications

Learn more about the work that we do in the Stegh laboratory through our academic publications:

Original, peer-reviewed research articles

  1. Alexander H. Stegh, Olaf Schickling, Andreas Ehret, Carsten Scaffidi, Christoph Peterhänsel, Thomas G. Hofmann, Ingrid Grummt, Peter H. Krammer and Marcus E. Peter (1998). DEDD, a novel DED containing protein that is targeted to the nucleolus. EMBO J. 20: 5974-5986.
  2. Alexander H. Stegh, Harald Herrman, Dieter Weisenberger, Peter Lichter, Peter H. Krammer and Marcus E. Peter (2000). Identification of the cytolinker plectin as a major early in vivo substrate for caspase-8 during TNF-R and CD95-mediated apoptosis. Molecular and Cellular Biology20:5665-79.
  3. Olaf Schickling, Alexander H. Stegh, Johnnie Byrd, and Marcus E. Peter (2001). Nuclear localization of DEDD leads to caspase-6 activation through its death effector domain and inhibition of RNA polymerase I dependent transcription. Cell Death and Differentiation8:1175-1168.
  4. Alexander H. Stegh, Bryan C. Barnhart, Jörg Volkland, Alicia Algeciras-Schimnich, Ning Ke, John C. Reed, and Marcus E. Peter (2002). Inactivation of caspase-8 on mitochondria of Bcl-xL expressing MCF7-Fas cells: Role for the BAR protein. Journal of Biological Chemistry. 277:4351-60.
  5. Justine C. Lee, Olaf Schickling, Alexander H. Stegh, Robert Oshima, Gerald M. Cohen, and Marcus E. Peter (2002). DEDD regulates degradation of intermediate filaments during apoptosis. Journal of Cell Biology.158:1051-66.
  6. Alexander H. Stegh, Hyunggee Kim, Robert M. Bachoo, Kristin L. Forloney, Jessica DeFrances, Jean Zhang, Harald Schulze, Kevin Park, Gregory J. Hannon, Junying Yuan, David N. Louis, Ronald A. DePinho, and Lynda Chin (2007). Bcl2L12 inhibits post-mitochondrial apoptosis signaling in GBM. Genes and Development. 21:98-111.
  7. Jayne M. Stommel, Alec C. Kimmelmann, Haoqiang Ying, Roustem Nabioullin, Aditya H.  Ponuguti, Ruprecht Wiedemeyer, Alexander H. Stegh, James E. Bradner, Cameron C. Brennan, Lynda Chin, and Ronald A. DePinho (2007). Co-activation of multiple RTKs influences the response to targeted therapies in human glioblastoma cells. Science. 318:287-90.
  8. Alexander H. Stegh, Santosh Kesari, John E. Mahoney, Kristin L. Forloney, Alexei Protopopov, David N. Louis, Lynda Chin, and Ronald A. DePinho (2008). Bcl2L12 inhibits effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma. Proceedings of the National Academy of Sciences.105:10703-10708.
  9. Alexander H. Stegh*, Cameron C. Brennan, John E. Mahoney, Kirstin L. Forloney, Janina P. Luciano, Alexei Protopopov, Lynda Chin, and Ronald A. DePinho* (2010). Glioma Oncoprotein Bcl2L12 inhibits the p53 tumor suppressor. Genes and Development. 24:2194-204. * co-corresponding authorsFeatured in:Nature Reviews Cancer 10, 741 (November 2010)
  10. Zhihu Ding, Chang-Jiun Wu, Gerald C. Chu, Yonghong Xiao, Dennis Ho, Jingfang Zhang, Samuel R. Perry, Emma S. Labrot, Xiaoqiu Wu, Rosina Lis, Yujin Hoshida, David Hiller, Baoli Hu, Shan Jiang, Hongwu Zheng, Alexander H. Stegh, Kenneth L. Scott, Sabina Signoretti, Nabeel Bardeesy, Y. Alan Wang, David E. Hill, Todd R. Golub, Meir J. Stampfer, Wing H. Wong, Massimo Loda, Lorelei Mucci, Lynda Chin, and Ronald A. DePinho (2011). SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature. 470:269-73.
  11. COVER: Samuel A. Jensen, Emily S. Day, Caroline H. Ko, Lisa A. Hurley, Janina P. Luciano, Fotini M. Kouri, Timothy J. Merkel, Andrea J. Luthi, Pinal Patel, Joshua I. Cutler, Weston L. Daniel, Alexander W. Scott, Matthew W. Rotz, Thomas J. Meade, David A. Giljohann, Chad A. Mirkin, and Alexander H. Stegh (2013). RNAi-based spherical nucleic acid nanoparticle conjugates as a novel therapeutic paradigm for Glioblastoma. Sci Transl Med. 2013. 5:209ra152. Featuredin:US News, FoxNews, Genetic Engineering & Biotechnology News, WGNTV, Chicago Tribune, Chicago Sun-Times, WGNTV, Chemical & Engineering News, Neurology Today, Science, Nature Medicine, Molecular Therapy, The Guardian.
  12. Samuel A. Jensen, Andrea E. Calvert, Giora Volpert, Fotini M. Kouri, Lisa A. Hurley, Janina P. Luciano, Yongfei Wu, Alexandra Chalastanis, Anthony H. Futerman, Alexander H. Stegh (2014) Bcl2L13 is a ceramide synthase inhibitor in glioblastoma. Proceedings of the National Academy of Sciences.111:5682-7.
  13. Markus A. Queisser, Laura A. Dada, Nimrod Deiss-Yehiely, Martin Angulo, Guofei Zhou, Fotini M. Kouri, Lawrence M. Knab, Jing Liu, Alexander H. Stegh, Malcolm M. DeCamp, G. R. Scott Budinger, Navdeep S. Chandel, Aaron Ciechanover, Kazuhiro Iwai, and Jacob I. Sznajder (2014).  HOIL-1L functions as the PKCζ ubiquitin ligase to promote lung tumor growth. Am J Respir Crit Care Med.190:688-98.
  14. Yasuyuki Yoshida, Tomoko Ozawa, Tsun-Wen Yao, Wang Shen, Dennis Brown, Andrew T. Parsa, Jeffrey J. Raizer, Shi-Yuan Cheng, Alexander H. Stegh, Andrew P. Mazar, Francis J. Giles, Jann N. Sarkaria, Nicholas Butowski, Theodore Nicolaides, and  C. David James (2014). NT113, a Pan-ERBB Inhibitor with High Brain Penetrance, Inhibits the Growth of Glioblastoma Xenografts with EGFR Amplification. Mol Cancer Ther.13:2919-29.
  15. COVER: Fotini M. Kouri, Lisa A. Hurley, Weston L. Daniel, Emily S. Day, Youjia Hua, Liangliang Hao, Chian-Yu Peng, Timothy J. Merkel, Markus A. Queisser, Carissa Ritner, Hailei Zhang, C. David James, Jacob I Sznajder, Lynda Chin, David A. Giljohann, John A. Kessler, Marcus E. Peter, Chad A. Mirkin, and Alexander H. Stegh (2015). miR-182 integrates apoptosis, growth and differentiation programs in Glioblastoma. Genes and Development. 29: 732-45. Featured in:Bioportfolio, MedicalXpress, Science Daily, Machineslikeu,s redOrbit, FoxNews, Neural Cell News, Science 2.0, AZoNano.com, ScienceCodex
  16. Jessica Rouge, Timothy Sita, Liangliang Hao, Fotini Kouri, William Briley, Alexander H. Stegh, and Chad Mirkin (2015). Ribozyme-Spherical Nucleic Acids. Journal of the American Chemistry Society.137:10528-31.
  17. Rintaro Hashizume, Ali Zhang, Sabine Mueller, Michael D. Prados, Rishi R. Lulla, Stewart S. Goldman, Amanda M. Saratsis, Andrew P. Mazar, Alexander H. Stegh, Shi-Yuan Cheng, Craig Horbinski, Daphne A. Haas-Kogan, Jann N. Sarkaria, Todd Waldman, and Charles David James. (2016). Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth. Neuro Oncol.18:1519-1528.
  18. Timothy L. Sita, Fotini M. Kouri, Lisa A. Hurley, Timothy J. Merkel, Alexandra Chalastanis, Jasmine L. May, Serena T. Ghelfi, Lisa E. Cole, Thomas C. Cayton, Stacey N. Barnaby, Anthony J. Sprangers, Nikunjkumar Savalia, C.David James, Andrew Lee, Chad A. Mirkin, and Alexander H. Stegh. (2017). Dual bioluminescence and near-infrared fluorescence monitoring to evaluate gene regulatory activity of Spherical Nucleic Acid nanoconjugates in vivo. Proceedings of the National Academy of Sciences.114:4129-4134.
  19. Andrea E. Calvert, Alexandra Chalastanis, Yongfei Wu, Lisa A. Hurley, Fotini M. Kouri, Yingtao Bi, Maureen Kachman, Jasmine L. May, Elizabeth Bartom, Youjia Hua, Rama K. Mishra, Gary E. Schiltz, Oleksii Dubrovskyi, Andrew P. Mazar, Marcus E. Peter, Hongwu Zheng, C. David James, Charles F. Burant, Navdeep S. Chandel, Ramana V. Davuluri, Craig Horbinski, and Alexander H. Stegh (2017). Cancer-associated IDH1 promotes growth and resistance to targeted therapies in the absence of mutation. Cell Reports. In press.

Editorials, Reviews, Book Chapters

  1. Alexander H. Stegh and Marcus E. Peter (2001). Apoptosis and caspases. Cardiology Clinics19: 13-29.
  2. Frank B. Furnari, Tim Fenton, Robert M. Bachoo, Akitake Mukasa, Jayne Stommel, Alexander H. Stegh, Keith Ligon, David N. Louis, Cameron Brennan, Lynda Chin, Ronald A. DePinho, Webster K. Cavenee (2007). Malignant Glioma: dysfunctional pathways and inroads to therapy. Genes and Development. 21: 2683-2710.
  3. Alexander H. Stegh*, Lynda Chin, David N. Louis, and Ronald A. DePinho* (2008). What drives apoptosis resistance and propensity for necrosis in glioblastoma? A role for Bcl2L12 as a multi-functional cell death regulator. Cell Cycle.7:2833-9. * co-corresponding authors
  4. Alexander H. Stegh* and Ronald A. DePinho* (2011). Beyond caspase inhibition: Bcl2L12 inhibits the p53 tumor suppressor. Cell Cycle.10:33-8. * co-corresponding authors
  5. Alexander H. Stegh (2011). Cell Death Signaling in Glioblastoma Multiforme: Role of the Bcl2L12 Oncoprotein. Tumors of the Central Nervous System. Edited by M.A. Hayat. Springer.
  6. Alexander H. Stegh (2012). Targeting the p53 signaling pathway in cancer therapy - the promises, challenges and perils. Expert Opin Ther Targets 16:67-83.
  7. Fotini M. Kouri, Samuel A. Jensen, Alexander H. Stegh (2012). The Role of Bcl-2 Family Proteins in Therapy Responses of Malignant Astrocytic Gliomas: Bcl2L12 and Beyond. ScientificWorldJournal. 2012:838916.
  8. Alexander H. Stegh (2012). Toward personalized cancer nanomedicine - past, present, and future. Integr Biol (Camb). 5:48-65. (amongst the Top 10 cited journal papers of the year)
  9. Chad A. Mirkin and Alexander H. Stegh (2014). Spherical nucleic acids for precision medicine. Oncotarget. 5:9-10.
  10. Timothy L. Sita and Alexander H. Stegh (2014). Nanoparticle Conjugates for Small Interfering RNA Delivery. Encyclopedia of Molecular Cell Biology and Molecular Medicine.
  11. Alexander H. Stegh, Chad A. Mirkin, Thomas C. Meade. Co-Editors: Cancer Treatment and Research series, Springer Books, Volume: Nanotechnology-Based Precision Tools for the Detection and Treatment of Cancer. 2015
  12. Stacey N. Barnaby, Timothy L. Sita, Sarah Hurst Petrosko,  Alexander H. Stegh* and Chad A. Mirkin* (2015). Therapeutic Applications of Spherical Nucleic Acids. Springer Books, Volume Nanotechnology-Based Precision Tools for the Detection and Treatment of Cancer. * co-corresponding authors
  13. Fotini M. Kouri, Carissa Ritner, and Alexander H. Stegh (2016). miRNA-182 and the regulation of the glioblastoma phenotype – toward miRNA-based precision therapeutics. Cell Cycle. 14:3794-800.

Proceedings and non-refereed papers

  1. 1. Alexander H. Stegh (1999). Characterization of effector mechanisms during CD95 mediated apoptosis. Futura, 2:133-134
  2. 2. Alexander H. Stegh (2001). Effector mechanisms of CD95-mediated apoptosis. Futura16:123-126.
  3. 3.  Alexander H. Stegh (2015). RNAi therapies. Invited contribution as a leader in the field of RNAi-based therapeutics for NCI’s Office of Cancer Nanotechnology Research “Cancer Nanotechnology Plan” (CaNanoPlan 2015) - NCI strategic document describing the current state of the field of cancer nanotechnology as well as outlining the future directions of the field. 

Abstracts

Oral presentations:

  1. Cancer-associated IDH1 inhibits growth and apoptosis in the absence of mutation. Annual meeting of the Society for Neuro-Oncology (SNO), San Antonio 2015.
  2. Cancer-associated IDH1 inhibits growth and apoptosis in the absence of mutation. Keystone meeting, New Frontiers in Understanding Tumor Metabolism, Banff, Alberta, 2016

Poster presentations:

  1. Alexander H. Stegh*, Hyunggee Kim, Robert M. Bachoo, Kristin L. Forloney, Jessica DeFrances, Jean Zhang, Harald Schulze, Kevin Park, Gregory J. Hannon, Junying Yuan, David N. Louis, Ronald A. DePinho, and Lynda Chin. Bcl2L12 inhibits post-mitochondrial apoptosis signaling in GBM. The 6th International Cell Death Symposium on "The Mechanisms of Cell Death", Angra dos Reis, Brazil, 2006.
  2. Alexander H. Stegh*, Hyunggee Kim, Robert M. Bachoo, Kristin L. Forloney, Jessica DeFrances, Jean Zhang, Harald Schulze, Kevin Park, Gregory J. Hannon, Junying Yuan, David N. Louis, Ronald A. DePinho, and Lynda Chin. Bcl2L12 inhibits post-mitochondrial apoptosis signaling in GBM. Keystone Symposium on “Apoptotic and Non-Apoptotic Cell Death Pathways”, Monterey, 2007.
  3. Alexander H. Stegh*, Cameron Brennan, John A. Mahoney, Kristin L. Forloney, Harry T. Jenq , Janina P. Luciano, Alexei Protopopov, Lynda Chin, and Ronald A. DePinho. Bcl2L12 inhibits the tumor suppressor activity of p53. AACR Annual Meeting, Denver, CO, 2009.
  4. Alexander H. Stegh*, Cameron Brennan, John A. Mahoney, Kristin L. Forloney, Harry T. Jenq , Janina P. Luciano, Alexei Protopopov, Lynda Chin, and Ronald A. DePinho. Bcl2L12 inhibits the tumor suppressor activity of p53. SNO Annual Meeting, Montreal, Canada, 2010.
  5. Samuel L. Jensen*, Emily S. Day, Caroline H. Ko, Lisa A. Hurley, Janina P. Luciano, Timothy J. Merkel, Joshua I. Cutler, Weston L. Daniels, Alexander W. Scott, Thomas J. Meade, David A. Giljohann, Chad A. Mirkin, and Alexander H. Stegh. Systemic delivery of tumor-penetrating RNAi- based spherical nucleic acid nanoparticle conjugates for the treatment of Glioblastoma. SNO Annual Meeting, Orange County, CA, 2011.
  6. Fotini M*. Kouri, Lisa M. Hurley, Janina P. Luciano, Hailei Zhang, Lynda Chin, and Alexander H. Stegh. miR-182 regulates therapy susceptibility in GBM by targeting the Bcl2L12 oncoprotein. SNO Annual Meeting, Orange County, CA, 2011.
  7. Samuel L. Jensen, Fotini M. Kouri, Andrea Calvert, Lisa M. Hurley, Janina, P. Luciano, Alexander H. Stegh. Glioma oncoprotein Bcl2L13 is a ceramide synthase inhibitor. SNO Annual Meeting, Orange County, CA, 2011.
  8. Samuel L. Jensen*, Emily S. Day, Caroline H. Ko, Lisa A. Hurley, Janina P. Luciano, Timothy J. Merkel, Joshua I. Cutler, Weston L. Daniels, Alexander W. Scott, Thomas J. Meade, David A. Giljohann, Chad A. Mirkin, and Alexander H. Stegh. Systemic delivery of tumor-penetrating RNAi- based spherical nucleic acid nanoparticle conjugates for the treatment of Glioblastoma. AACR Annual Meeting, Chicago, IL 2012.
  9. Fotini M. Kouri*, Lisa M. Hurley, Janina P. Luciano, Hailei Zhang, Lynda Chin, and Alexander H. Stegh. miR-182 regulates therapy susceptibility in GBM by targeting the Bcl2L12 oncoprotein. SNO AACR Annual Meeting, Chicago, IL, 2012
  10. Samuel L. Jensen*, Fotini M. Kouri, Andrea Calvert, Lisa M. Hurley, Janina, P. Luciano, Alexander H. Stegh. Glioma oncoprotein Bcl2L13 is a ceramide synthase inhibitor. AACR Annual Meeting, Chicago, IL, 2012.
  11. Samuel L. Jensen, Emily S. Day, Caroline H. Ko, Lisa A. Hurley, Janina P. Luciano, Timothy J. Merkel, Joshua I. Cutler, Weston L. Daniels, Alexander W. Scott, Thomas J. Meade, David A. Giljohann, Chad A. Mirkin, and Alexander H. Stegh. Systemic delivery of tumor-penetrating RNAi- based spherical nucleic acid nanoparticle conjugates for the treatment of Glioblastoma. Cell Symposium, Hallmarks of Cancer, San Francisco, CA, 2012.
  12. Fotini M. Kouri*, Lisa M. Hurley, Janina P. Luciano, Hailei Zhang, Lynda Chin, and Alexander H. Stegh. miR-182 regulates therapy susceptibility in GBM by targeting the Bcl2L12 oncoprotein. Cell Symposium, Hallmarks of Cancer, San Francisco, CA, 2012.

Patents

  1. Alexander H. Stegh, Hyungee Kim, Lynda Chin, Ronald A. DePinho (2004). Bcl2L12 polypeptide activators and inhibitors. PCT/US2004/012591
  2. Alexander H. Stegh, Samuel L. Jensen, Janina P. Luciano, Caroline H. Ko, David Giljohann, Chad A. Mirkin (2012). Nanoconjugates able to cross the blood-brain barrier. PCT/US2012/055635.

Media Coverage and Appearances

  1. 2013 WGNTV television interview about my laboratory’s paper Jensen et al., 2013, Science Translational Medicine
  2. 2013 SWR2, German public radio interview about my laboratory’s paper Jensen et al., 2013, Science Translational Medicine
  3. 2013, 2015 Interview with various media outlets about my laboratory’s papers Jensen et al., 2013, Science Translational Medicine, and Kouri et al., 2015, Genes and Development, including US News, FoxNews, Genetic Engineering & Biotechnology News, WGNTV, Chicago Tribune, Chicago Sun-Times, WGNTV, Chemical & Engineering News, Neurology Today, Science, Nature Medicine, Molecular Therapy, The Guardian, Bioportfolio, MedicalXpress, Science Daily, Machineslikeu,s redOrbit, FoxNews, Neural Cell News, Science 2.0, AZoNano.com, ScienceCodex an RNAi-Based Therapy for Glioblastoma. Sci Transl Med. 2013 Oct 30;5(209):209ra152.